Characteristics of subjective cognitive decline associated with amyloid positivity

Janssen, Olin; Jansen, Willemijn J.; Vos, Stephanie J.B.; Boada, Merçé; Parnetti, Lucilla; Gabryelewicz, Tomasz; Fladby, Tormod; Molinuevo, José Luís; Villeneuve, Sylvia; Hort, Jakub; Epelbaum, Stéphane; Lleó, Alberto; Engelborghs, Sebastiaan; Flier, Wiesje M. van der; Landau, Susan; Popp, Julius; Wallin, Anders; Scheltens, Philip; Rikkert, Marcel G M Olde; Snyder, Peter J.; Rowe, Chris; Chételat, Gaël; Ruiz, Agustín; Marquié, Marta; Chipi, Elena; Wolfsgruber, Steffen; Heneka, Michael T.; Boecker, Henning; Peters, Oliver; Jarholm, Jonas; Rami, Lorena; Tort‐Merino, Adrià; Binette, Alexa Pichet; Poirier, Judes; Rosa‐Neto, Pedro; Cerman, Jiří; Dubois, Bruno; Teichmann, Marc; Alcolea, Daniel; Fortea, Juan; Sánchez-Saudinós, María Belén; Ebenau, Jarith L.; Pocnet, Cornelia; Eckerström, Marie; Thompson, Louisa I.; Villemagne, Victor L.; Buckley, Rachel F.; Burnham, Samantha; Delarue, Marion; Freund‐Levi, Yvonne; Wallin, Åsa; Ramakers, Inez H.G.B.; Tsolaki, Magda; Hampel, Harald; Spiru, Luiza; Jessen, Frank; Visser, Pieter Jelle

doi:10.1002/alz.12512

Cited by 33 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding concerning the association between SMC and brain amyloid index is consistent with the results of several studies on SMC–Aβ association using amyloid PET imaging or plasma Aβ measurements in non-demented individuals ( Amariglio et al, 2012 ; Perrotin et al, 2012 ; Kryscio et al, 2014 ; Cantero et al, 2016 ; Kim et al, 2019 ; Hong et al, 2021 ; Janssen et al, 2021 ; Tort-Merino et al, 2021 ). Although some studies using amyloid PET imaging did not identify a significant SMC–Aβ association ( Chetelat et al, 2010 ; Rodda et al, 2010 ), these reported a trend toward an SMC–Aβ association ( Chetelat et al, 2010 ; Rodda et al, 2010 ).…”

Section: Discussionsupporting

confidence: 92%

“…Although some studies using amyloid PET imaging did not identify a significant SMC-Aβ association (Chetelat et al, 2010;Rodda et al, 2010), these reported a trend toward an SMC-Aβ association (Chetelat et al, 2010;Rodda et al, 2010). These findings suggests that SMC is a risk factor for AD or related cognitive impairment (Commissaris et al, 1994(Commissaris et al, , 1998Winblad et al, 2004;Reid and Maclullich, 2006;Reisberg et al, 2008;Jessen et al, 2010Jessen et al, , 2014aChoe et al, 2018;Janssen et al, 2021;Tort-Merino et al, 2021) because Aβ pathology is the earliest key pathology of AD (Braak and Braak, 1991;Tobiansky et al, 1995;Jack et al, 2010). In addition, Aβ may show a mediation effect on the association between SMC and AD or related cognitive impairment.…”

Section: Discussionmentioning

confidence: 98%

“…A growing body of evidence suggests that SMC is a risk factor for AD or related cognitive impairment ( Commissaris et al, 1994 , 1998 ; Winblad et al, 2004 ; Reid and Maclullich, 2006 ; Reisberg et al, 2008 ; Jessen et al, 2010 , 2014a , 2014b ; Choe et al, 2018 ; Janssen et al, 2021 ; Tort-Merino et al, 2021 ). In particular, SMC in cognitive normal (CN) state, i.e., subjective cognitive decline (SCD), has been proposed as an early symptom of AD, prior to objective cognitive dysfunction ( Winblad et al, 2004 ; Reid and Maclullich, 2006 ; Reisberg et al, 2008 ; Jessen et al, 2010 , 2014a , 2014b ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Brain Amyloid Index as a Probable Marker Bridging Between Subjective Memory Complaint and Objective Cognitive Performance

Choe

Suh²,

Lee³

et al. 2022

Front. Neurosci.

View full text Add to dashboard Cite

BackgroundThe association between types of subjective memory complaint (SMC), poor objective cognitive performance, and brain Aβ deposition have been poorly understood. We investigated the association between types of SMC and objective global cognitive performance, then assessed whether this association is mediated by the brain amyloid prediction index (API).MethodsIn total, 173 non-demented older adults [63 cognitively normal (CN) and 110 mild cognitive impairment (MCI)] underwent comprehensive clinical assessments. Objective global cognitive performance and brain amyloid index were measured using the total score (TS) of the Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological battery and API, respectively. In total, four items of SMC from the subjective memory complaints questionnaire (SMCQ) (SMCQ1: a feeling of memory problem; SMCQ2: the feeling of worse memory than 10 years ago; SMCQ3: the feeling of worse memory than others of similar age; or SMCQ4: the feeling of difficulty in everyday life) in global memory function were assessed.ResultsIn non-demented and participants with MCI, SMCQ3-positive and SMCQ4-positive groups were associated with decreased TS. In participants with MCI, the SMCQ3-positive group was associated with increased API, and API was associated with decreased TS, but the SMCQ4-positive group did not. In addition, the association between the SMCQ3-positive group and poor TS disappeared when API was controlled as a covariate, indicating that API has a mediation effect.ConclusionThe present findings suggest that SMC, a feeling of worse memory performance than others in a similar age group, in the older adults without dementia is associated with poor objective cognitive performance via increased brain amyloid index.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Brain Amyloid Index as a Probable Marker Bridging Between Subjective Memory Complaint and Objective Cognitive Performance

Choe

Suh²,

Lee³

et al. 2022

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…SCD is not specific to AD and can also be caused by normal aging, depression, and other psychiatric and neurologic disorders [5]. In addition, a recent meta-analysis reported substantial variation of the proportion of SCD cases with amyloid pathology among individual samples, depending on the specific recruitment criteria and settings [6]. In those SCD cases, who progress to dementia, DAT is the most common, but other dementia types also occur [7].…”

Section: Introductionmentioning

confidence: 99%

Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients

Gerards

Schild

Meiberth

et al. 2022

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

Introduction: Several recent research studies show high performance of blood biomarkers to identify Alzheimer’s disease also in the pre-dementia mild cognitive impairment (MCI) stage, but data from the routine clinical care memory clinic setting are needed. Methods: We examined plasma samples of 144 memory clinic patients, including dementia of Alzheimer type (DAT, n = 54), MCI (n = 57), and subjective cognitive decline (SCD, n = 33), who either presented as self-referrals or were referred by general practitioners or neurologists or psychiatrists. The plasma biomarkers, amyloid-beta42 (Aß42), amyloid-beta40 (Aß40), phospho-Tau181 (pTau181), total-tau (tTau), and neurofilament light (NFL), as well as different ratios, were measured using the ultrasensitive single molecule array (Simoa) immunoassay technology. Statistical analysis including Kruskal-Wallis test, linear regression, and receiver operating characteristics analyses was performed. Results: Of the single markers, we observed statistically significant group effects of pTau181 (H(2) = 34.43, p < 0.001) and NFL (H(2) = 27.66, p < 0.001). All individual group comparisons of pTau181 were significant, while the contrast of SCD versus MCI for NFL was not significant. In addition, the ratios of Aß42/Aß40 (H(2) = 7.50, p = 0.02) and pTau181/Aß42 (H(2) = 25.26, p < 0.001) showed significant group effects with significant difference between all groups for pTau181/Aß42 and an SCD versus MCI difference for Aß42/Aß40. PTau181 showed the highest area under the curve of 0.85 for the discrimination of SCD and DAT with a sensitivity of 80% and a specificity of 79% at a cut-off of 12.2 pg/mL. Age influenced Aß42, Aß40, and NFL concentrations. Conclusion: Plasma pTau181 and NFL, as well as the ratios Aß42/Aß40 and pTau181/Aß42, are biomarkers, which can differentiate diagnostic groups in a memory clinic setting outside of research studies.

show abstract

“…In the stable amyloid-negative group, depressive symptoms may be associated with increased awareness of cognitive failures, consequently leading to seek medical consultation. Studies on subjective cognitive impairment (SCI) have shown that patients with a history of medical help-seeking behaviour had lower amyloid and higher depressive symptoms [28], and that feelings of worse cognitive performance were not predicted by amyloid positivity in younger individuals [29]. Although patients undergoing amyloid PET in our Clinic do have some degree of objective impairment by definition [16], a similar mechanism to that seen in SCI may apply to the stable amyloid-negative group.…”

Section: Discussionmentioning

confidence: 64%

Prevalence of Depressive Symptoms in a Memory Clinic Cohort: A Retrospective Study

Loreto

Fitzgerald

Golemme

et al. 2022

JAD

View full text Add to dashboard Cite

Background: Depression has been suggested to be a cause of reversible cognitive impairment but also a risk factor for neurodegenerative disease. Studies suggest that depression prevalence may be high in early onset dementia, particularly Alzheimer’s disease, but this has not been systematically assessed in a biomarker-validated clinical dementia cohort to date. Objective: To examine the prevalence, features, and association with amyloid pathology of lifetime depressive symptoms in a memory clinic cohort meeting appropriate use criteria for amyloid PET imaging. Methods: We included 300 patients from a single-center memory clinic cohort that received diagnostic biomarker evaluation with amyloid PET imaging according to appropriate use criteria. History of lifetime depressive symptoms was retrospectively assessed through structured review of clinical correspondence. Results: One hundred forty-two (47%) patients had a history of significant depressive symptoms (‘D+’). Of these, 89% had ongoing symptoms and 60% were on antidepressants at the time of presentation to our Clinic. Depressive symptoms were equally highly prevalent in the amyloid-positive and the heterogeneous group of amyloid-negative patients. Conclusion: Approximately half of patients who meet appropriate use criteria for amyloid PET had a history of depressive symptoms. We suggest that depression is an important feature of both neurodegenerative and non-neurodegenerative cognitive impairment and may contribute to the diagnostic uncertainty behind referral to amyloid PET.

show abstract

Characteristics of subjective cognitive decline associated with amyloid positivity

Cited by 33 publications

References 38 publications

Brain Amyloid Index as a Probable Marker Bridging Between Subjective Memory Complaint and Objective Cognitive Performance

Brain Amyloid Index as a Probable Marker Bridging Between Subjective Memory Complaint and Objective Cognitive Performance

Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients

Prevalence of Depressive Symptoms in a Memory Clinic Cohort: A Retrospective Study

Contact Info

Product

Resources

About